Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Expert consensus on joint diagnosis and treatment of multimorbidity of upper airway allergic diseases in children].

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery·2026
Same author

Galectin-9-driven immune evasion constrains radiotherapy-induced systemic antitumor immunity.

Journal for immunotherapy of cancer·2026
Same author

Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting.

Journal of hematology & oncology·2026
Same author

Design of MEMS Gas Sensors and Integration for Multiple Gas Classification for Lithium-Ion Battery Thermal Runaway Warning.

Materials (Basel, Switzerland)·2026
Same author

Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.

Journal of hematology & oncology·2026
Same author

Ru-Catalyzed Asymmetric Hydrogenation of γ‑Amino Ketones.

JACS Au·2026

Related Experiment Video

Updated: May 3, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Ibrutinib for B cell malignancies.

Aileen Novero, Pavan M Ravella, Yamei Chen

  • 1Institute of Hematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, China. Delong_liu@nymc.edu.

Experimental Hematology & Oncology
|January 30, 2014
PubMed
Summary
This summary is machine-generated.

Bruton's agammaglobulinemia tyrosine kinase (BTK) plays a key role in B-cell cancers. Inhibiting BTK with ibrutinib offers a promising new strategy for treating these malignancies.

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Related Experiment Videos

Last Updated: May 3, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Bruton's agammaglobulinemia tyrosine kinase (BTK) is crucial for B-lymphocyte development and survival.
  • Dysregulation of BTK signaling contributes to the pathogenesis of B-cell malignancies.
  • Targeting BTK activity presents a novel therapeutic strategy for B-cell cancers.

Purpose of the Study:

  • To review the role of BTK in B-cell signaling and microenvironment interactions.
  • To summarize the clinical efficacy of the BTK inhibitor ibrutinib in B-cell malignancies.

Main Methods:

  • Literature review of BTK function in B-cell biology.
  • Analysis of molecular interactions in the B-cell tumor microenvironment.
  • Summary of clinical trial data for ibrutinib in B-cell malignancies.

Main Results:

  • BTK is essential for B-cell signaling pathways and survival.
  • Ibrutinib, a BTK inhibitor, demonstrates significant responses in B-cell malignancies.
  • Ibrutinib irreversibly binds to BTK, inhibiting its activity.

Conclusions:

  • BTK is a critical target for B-cell malignancy treatment.
  • Ibrutinib shows promise as a targeted therapy for B-cell cancers.
  • Further research into BTK inhibition is warranted for B-cell malignancies.